Evidence map›Paper›PMID 41669265›Full record

ArticleFrontiers in oncology2025

Recurrent CIC-rearranged sarcoma of central nervous system: a clinicopathological case report.

Shan Jiang, Kay Ka-Wai Li, Jingqi Hu, Yun Guan, Rui-Ze Zhu, Hou-Shi Xu, Mao-Yuan Sun, Bei-Ning Liu, Hui-Hui Chai, Yue Wang and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Integrated bioinformatics to identify and validate the role of oxidative stress-related gene EPHX2 in laryngeal cancer.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shan JiangDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Kay Ka-Wai LiDepartment of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Jingqi HuDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Yun GuanNational Center for Neurological Disorders, Shanghai, China.
Rui-Ze ZhuDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Hou-Shi XuDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Mao-Yuan SunDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Bei-Ning LiuDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Hui-Hui ChaiDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Yue WangDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Qi-Sheng TangDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Ho-Keung NgDepartment of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Zhi-Feng ShiDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CIC-rearranged sarcoma (CRS) is a subgroup of small round blue cell tumors similar to Ewing's sarcoma but lacking the EWSR1 gene translocation. It is characterized by a CIC gene rearrangement on chromosome 19q13, with the most common partner gene being DUX4. In 2021, the WHO classification of central nervous system tumors (5th edition) introduced a new pathological classification for CRS based on bone and soft tissue tumor classifications, categorizing it as mesenchymal non-meningeal epithelial tumors. Primary CIC::DUX4 rearrangement sarcoma in the central nervous system is extremely rare, with no established standard treatment and a very poor prognosis. Herein, we present a case of intracranial CIC::DUX4 rearrangement diagnosed using DNA methylation classifiers and multiple omics diagnosis techniques. We also document the disease progression after chemoradiation therapy and subsequent

Indexed as

case reportCIC rearranged sarcomaCyberKnifemethylation classifiersMTB

Identifiers

PMID41669265
PMCPMC12883352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.